Clinical trial NCT06584149: BAR As a Mortality Predictor in Septic AKI
Official title: The Role of Blood Urea Nitrogen to Serum Albumin Ratio in the Prediction of Mortality in Septic Acute Kidney Injury Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Kidney Injury
Sepsis
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2024-09-04
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This prospective study will be conducted on patients with septic acute kidney injury. After admission of the patient to ICU in Ain Shams University Hospitals

Brief summary: The aim of this study is to investigate the prognostic value of Blood Urea Nitrogen to serum Albumin ratio in septic Acute Kidney Injury patients Follow-up will be conducted for all enrolled patients for 30 days from admission to record mortality and the cause of death.

Detailed description: A complete medical history will be obtained from all patients including age, sex, comorbidities, cause of sepsis, and SOFA and APACHE II scores at admission.

Blood samples will be collected within 24 hours of AKI diagnosis for analysis of Blood Urea Nitrogen (BUN) and serum Albumin levels.

Blood Urea Nitrogen to serum Albumin ratio (B/A) will be calculated by dividing the BUN of a patient by their serum Albumin levels.

Laboratory parameters also will include pH, lactate (Lac), base excess (BE), hemoglobin (Hb), platelet (PLT) count, white blood cell (WBC) count, bilirubin, hematocrit (HCT), creatinine (Cr), serum sodium (Na), serum potassium (K), serum calcium (Ca), serum magnesium (Mg), triglyceride (TG), aspartate aminotransferase (ALT), alanine aminotransferase (AST), prothrombin time (PT), and activated partial thromboplastin time (APTT) values.

Follow-up will be conducted for all enrolled patients for 30 days from admission to record mortality and the cause of death.

Study population will be divided into survival and non-survival groups based on their 30-day survival status

Eligibility criteria: Inclusion Criteria:

1. 18 - 60 years of age
2. Fulfilled the diagnostic criteria of Sepsis 3.0 (defined as a suspected or confirmed infection with a sequential organ failure assessment (SOFA) score of 2 or higher)
3. Developed AKI during hospitalization according to Kidney Disease: Improving Global Outcomes (KDIGO) guideline

Exclusion Criteria:

1. ICU length of stay\<24 h
2. AKI occurred before current hospital admission.
3. AKI is supposed to be secondary to causes other than sepsis.
4. Receiving renal replacement therapy at the time of admission.
5. Diagnosis with chronic kidney disease.
6. Diagnosis with liver failure.
7. Pregnant or lactating.
8. There was insufficient data for analysis.
9. Patients who had received Human serum Albumin infusion 3 days before ICU admission.

Primary outcomes:
measure: mortality
timeFrame: 30 days
Secondary outcomes:
measure: mechanical ventilation
timeFrame: 30 days
measure: stage-3 AKI
timeFrame: 30 days
measure: renal replacement therapy
timeFrame: 30 days
measure: septic shock
timeFrame: 30 days
measure: length of ICU stay
timeFrame: 30 days
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University
state: Abbassia
Study officials:
References: